Fig. 3
RORγt agonist 8-074 inhibits tumor growth in syngeneic models and improves anti‐PD‐1 therapy in LLC. a C57BL/6 inoculated with LLC cells were treated with a vehicle control, 8-074, or LYC-55716 at 50 mg/kg via i.p. injection, QD over two weeks (N = 5–8 per group, **P < 0.01 and ***P < 0.001). b Dose-escalation study of 8-074 treatment in LLC model. C57BL/6 mice bearing LLC tumors were randomly divided into four groups (n = 5–8 per group) and administered with 8-074 (0, 25, 50, 100 mg/kg) via i.p. injection, QD over two weeks. ***P < 0.001 and ****P < 0.0001, by 2-way ANOVA. c Mice were injected subcutaneously with 2 × 105 B16F10 cells or d 2 × 106 MC38 cells on C57BL/6 mice treated with RORγt agonist 8–074 via intraperitoneal injection, QD over two weeks. N = 5–8 per group. **P < 0.01 and ***P < 0.001. e Combination treatment of 8-074 and anti-PD-1 showed significant tumor reduction in the LLC model. N = 6 mice per group. ***P < 0.001, by 2-way ANOVA. f The images of tumors of mice in four groups were obtained from sacrificed mice at the end of this experiment. g Combination treatment of 8-074 and anti-PD-1 showed significant tumor reduction in the LLC model. N = 6 mice per group. Tumor growth curve of individual mice of the IgG group, anti-PD-1 group, 8-074 group, and the combination of anti-PD-1 antibody with 8-074 group. Tumor volume is represented as the mean ± SD. All error bars represent mean ± SD. Experiments were repeated three times with consistent results